DAVID KAPLAN: Open Payments
NPI 1134208994 · DANBURY, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,295 in 62 payments from 14 companies in 2025. Trend: 2023 $1,017 · 2024 $1,291 · 2025 $1,295
Food & beverage: $1,295
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $310 |
| Indivior Inc. | 6 | $187 |
| Braeburn Inc. | 9 | $164 |
| Otsuka America Pharmaceutical, Inc. | 8 | $162 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $154 |
| Neurocrine BioSciences, Inc. | 3 | $76 |
| Lundbeck LLC | 4 | $73 |
| ABBVIE INC. | 3 | $50 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
Products named: REXULTI, SUBLOCADE, BRIXADI, CAPLYTA, ARISTADA, LYBALVI, INGREZZA, VIVITROL.
Industry payments across NC — which companies pay providers there.
